Sartobind® Rapid A: Comparable High Product Quality As Protein A Resins At High Productivity

Processes to purify recombinant monoclonal antibodies (mAb) for therapeutic treatment are well established in the market. However, manufacturers are continuously improving their processes to lower patient risks and treatment costs.

The mAb capture step represents the current bottleneck in downstream processing. Protein A resins are diffusion-limited chromatography materials that require low flow rates to achieve a binding capacity above 30 g/L, which results in low productivity. Explore a novel chromatography membrane that combines high binding capacities with high flow rates for increased productivity while achieving comparable product quality as state-of-the-art protein A resins.

This novel technology increases productivity 10× compared to resins, which remains consistent during scale-up, and it purifies monoclonal antibodies with 10× less chromatography material used per batch, allowing for full utilization of the membrane within one batch. Plus, as a disposable consumable, it provides the opportunity to remove column handling in bioprocesses and resin reuse over multiple batches.